Stay updated with breaking news from Viewpoint Molecular. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fireside chat with newly appointed CEO, Thijs Spoor, today, February 22 at 1:30 PM ETCORALVILLE, IA / ACCESSWIRE / February 22, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company")
Viewpoint Molecular Targetin(TM) Commences Patient Enrollment in Phase 1 Imaging Study for VMT01 Program for Metastatic Melanoma ACCESSWIRE 11 Jun 2021, 00:05 GMT+10 - VMT01 Phase 1 imaging study followed by Phase 1/2a therapy study for the treatment of metastatic melanoma being conducted at Mayo Clinic - - Positive preclinical data have demonstrated that a single dose of [212Pb]-VMT01 has significantly arrested melanoma tumor growth and extended survival - - VMT01 imaging study provisional results expected in Q4 2021 - CORALVILLE, IA / ACCESSWIRE / June 10, 2021 / Viewpoint Molecular Targeti...
- VMT01 Phase 1 imaging study followed by Phase 1/2a therapy study for the treatment of metastatic melanoma being conducted at Mayo Clinic -- Positive preclinical data have demonstrated that a single dose
Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Closes $8 Million in First Tranche of Series A Financing Funds from Series A expected to propel two lead radiopharmaceutical programs, VMT01 and VMT- ?? -NET into Phase 1 imaging studies beginning before year-end 2020 and accelerate development of radioisotope production technologies CORALVILLE, IA / ACCESSWIRE / December 15, 2020 / viewpointmt.com Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic...